Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Novacyl Wuxi Pharmaceutical Co., Ltd.
WARNING LETTER
•Novacyl Wuxi Pharmaceutical Co., Ltd.•October 18, 2013

Novacyl Wuxi Pharmaceutical Co., Ltd. – FDA Warning Letter, Oct 18, 2013

Record Details

On December 19, 2014, the FDA issued a Warning Letter to Novacyl Wuxi Pharmaceutical Co. Ltd. following an inspection from October 14-18, 2013. The inspection revealed significant deviations from current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (APIs) and violations of CGMP regulations for finished pharmaceuticals (21 CFR Parts 210 and 211), rendering their products adulterated.

Key violations include: 1. **API CGMP Deviation:** Failure to manage laboratory systems with sufficient controls, leading to missing raw data, undocumented changes to integration parameters, lack of procedures for manual integration, shared passwords, and use of uncontrolled worksheets and chromatograms. An example cited was a discarded chromatogram showing an additional peak for an API. The firm's previous corrective actions were deemed insufficient. 2. **Finished Product CGMP Violations:** * Failure to properly document or investigate out-of-specification (OOS) results and other discrepancies (21 CFR 211.192), such as an OOS investigation for metal particles in a product that lacked root cause determination. * Failure to establish adequate laboratory controls, including scientifically sound specifications and test procedures (21 CFR 211.160(b)). * Failure to record all CGMP activities contemporaneously (21 CFR 211

Company
Novacyl Wuxi Pharmaceutical Co., Ltd.
Inspection date
October 18, 2013
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • David H. Jones
  • Thomas J. Cosgrove
View Company Profile

ID · 7595e0fd-0764-4926-910c-3c867bbe993c

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.160(b)21 CFR 211.188FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novacyl Wuxi Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.